Eli Lilly's obesity drug gets Medicare coverage for sleep apnea, CNBC reports-March 2024-www.financetom.com

Eli Lilly's obesity drug gets Medicare coverage for sleep apnea, CNBC reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Eli Lilly's obesity drug gets Medicare coverage for sleep apnea, CNBC reports

Jan 8, 2025 12:52 PM

Jan 8 (Reuters) - Eli Lilly's ( LLY ) popular obesity

drug Zepbound can now be covered by government-backed Medicare

drug plans, CNBC reported on Wednesday, citing the Centers for

Medicare & Medicaid Services.

(Reporting by Puyaan Singh in Bengaluru; Editing by Devika

Syamnath)

Previous page： O Reilly Automotive Insider Sold Shares Worth $2,667,481, According to a Recent SEC Filing Next page： Sarepta Therapeutics Q4 Non-GAAP Earnings, Revenue Rise

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

O Reilly Automotive Insider Sold Shares Worth $2,667,481, According to a Recent SEC Filing

Feb 26, 2025

04:47 PM EST, 02/26/2025 (MT Newswires) -- Jason Lee Tarrant, Executive Vice President, Store Operations & Sales, on February 25, 2025, sold 1,992 shares in O Reilly Automotive (ORLY) for $2,667,481. Following the Form 4 filing with the SEC, Tarrant has control over a total of 1,459 common shares of the company, with 1,398 shares held directly and 61 controlled...

Sarepta Therapeutics Q4 Non-GAAP Earnings, Revenue Rise

Feb 26, 2025

04:48 PM EST, 02/26/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) reported Q4 non-GAAP net earnings late Wednesday of $1.90 per diluted share, up from $0.82 a year earlier. Analysts polled by FactSet expected $2.00. Total revenue for the quarter ended Dec. 31 was $658.4 million, up from $396.8 million a year earlier. Analysts surveyed by FactSet expected $636.1...

Chemed Q4 Adjusted Earnings, Revenue Rise; 2025 Outlook Set

Feb 26, 2025

04:49 PM EST, 02/26/2025 (MT Newswires) -- Chemed ( CHE ) reported Q4 adjusted earnings late Wednesday of $6.83 per diluted share, up from $6.60 a year earlier. Three analysts surveyed by FactSet expected $6.78. Revenue for the quarter ended Dec. 31 was $640 million, up from $585.9 million a year earlier. Three analysts polled by FactSet expected $636.1 million....

Universal Health Services Q4 Adjusted Earnings, Revenue Increase -- Shares Rise After Hours

Feb 26, 2025

04:48 PM EST, 02/26/2025 (MT Newswires) -- Universal Health Services ( UHS ) reported Q4 adjusted earnings late Wednesday of $4.92 per diluted share, up from $3.13 a year earlier. Analysts polled by FactSet expected $4.14. Net revenue for the quarter ended Dec. 31 was $4.11 billion, up from $3.70 billion a year earlier. Analysts surveyed by FactSet expected $4.01...